Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Stroobant

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|August 2, 2021
Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-DioxygenaseArina Kozlova, Léopold Thabault, Maxime Liberelle, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2003
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 proteinYi Zhang, Pascal Chaux, Vincent Stroobant, et al.
Cancer Research|January 11, 2011
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastasesVéronique Corbière, Jacques Chapiro, Vincent Stroobant, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2010
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I moleculesBenoît Guillaume, Jacques Chapiro, Vincent Stroobant, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenaseLuc Pilotte, Pierre Larrieu, Vincent Stroobant, et al.
Immunological Reviews|November 26, 2002
Tumor-specific shared antigenic peptides recognized by human T cellsPierre Van Der Bruggen, Yi Zhang, Pascal Chaux, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2022
Parkinson's disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metaboliteIsaac P Heremans, Francesco Caligiore, Isabelle Gerin, et al.
Journal of Medicinal Chemistry|May 24, 2012
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibitionUte F Röhrig, Somi Reddy Majjigapu, Aurélien Grosdidier, et al.
Scientific Reports|September 26, 2020
Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteinsJoanna Abi Habib, Etienne De Plaen, Vincent Stroobant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2014
A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytesNathalie Demotte, René Bigirimana, Grégoire Wieërs, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|August 2, 2021
Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-DioxygenaseArina Kozlova, Léopold Thabault, Maxime Liberelle, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2003
A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 proteinYi Zhang, Pascal Chaux, Vincent Stroobant, et al.
Cancer Research|January 11, 2011
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastasesVéronique Corbière, Jacques Chapiro, Vincent Stroobant, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2010
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I moleculesBenoît Guillaume, Jacques Chapiro, Vincent Stroobant, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenaseLuc Pilotte, Pierre Larrieu, Vincent Stroobant, et al.
Immunological Reviews|November 26, 2002
Tumor-specific shared antigenic peptides recognized by human T cellsPierre Van Der Bruggen, Yi Zhang, Pascal Chaux, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2022
Parkinson's disease protein PARK7 prevents metabolite and protein damage caused by a glycolytic metaboliteIsaac P Heremans, Francesco Caligiore, Isabelle Gerin, et al.
Journal of Medicinal Chemistry|May 24, 2012
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibitionUte F Röhrig, Somi Reddy Majjigapu, Aurélien Grosdidier, et al.
Scientific Reports|September 26, 2020
Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteinsJoanna Abi Habib, Etienne De Plaen, Vincent Stroobant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2014
A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytesNathalie Demotte, René Bigirimana, Grégoire Wieërs, et al.
Pageof 9